MoneyWorks4Me

The revenue zoomed 10.31% to Rs. 1406.12 millions for the quarter ended September 2022 as compared to Rs. 1274.68 millions during the corresponding quarter last year.A meek growth of 2.98% was reported for the quarter ended September 2022 to Rs. 237.12  millions from Rs. 230.26 millions.Operating profit for the quarter ended September 2022 rose to 345.93 millions as compared to 327.31 millions of corresponding quarter ended September 2021.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202209 202109 % Var 202209 202109 % Var 202203 202103 % Var
Sales 1406.12 1274.68 10.31 2640.83 2496.57 5.78 4720.79 4229.08 11.63
Other Income 56.85 34.61 64.26 121.80 54.72 122.59 99.98 57.43 74.09
PBIDT 345.93 327.31 5.69 579.99 600.55 -3.42 1054.68 927.83 13.67
Interest 1.39 2.04 -31.86 5.50 5.79 -5.01 14.51 15.52 -6.51
PBDT 344.54 325.27 5.92 574.49 594.76 -3.41 1040.17 912.31 14.01
Depreciation 24.22 19.92 21.59 44.91 39.09 14.89 80.88 75.60 6.98
PBT 320.32 305.35 4.90 529.58 555.67 -4.70 959.29 836.71 14.65
TAX 83.20 75.09 10.80 142.34 148.38 -4.07 265.74 214.21 24.06
Deferred Tax 1.65 -2.46 -167.07 1.39 -0.90 -254.44 7.20 2.47 191.50
PAT 237.12 230.26 2.98 387.24 407.29 -4.92 693.55 622.50 11.41
Equity 200.30 200.30 0.00 200.30 200.30 0.00 200.30 200.30 0.00
PBIDTM(%) 24.60 25.68 -4.19 21.96 24.06 -8.70 22.34 21.94 1.83
Peers
Company Name CMP
Sun Pharma. Inds. 1835.50
Dr. Reddys Labs. 1171.10
Cipla 1371.45
Lupin 2144.70
Zydus Lifesciences 1153.00
View more..